Top Markets
Coin of the day
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Κατάταξη σε μετοχές #41184
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Τιμή μετοχής
$0.0001
Τελευταίος συγχρονισμός: 2026-08-11
Κεφαλαιοποίηση
$36.84K
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
-66.67%
Χώρα
US
Εμπόριο Amarantus BioScience Holdings, Inc. (AMBS)

Κατηγορία

Ιστορικό τιμής μετοχής για την Amarantus BioScience Holdings, Inc. (AMBS)
Υψηλότερη τιμή κλεισίματος: $0.00 στις 2026-08-01

Χαμηλότερη τιμή κλεισίματος: $0.00 στις 2010-09-01
Ιστορικό τιμής μετοχής της Amarantus BioScience Holdings, Inc. από 2010 έως 2026
Ετήσια απόδοση τιμής μετοχής
Έτος Απόδοση
2026 (TTM) 0.00%
2025 -45.33%
2024 -92.14%
2023 -34.21%
2022 -85.44%
2021 56.94%
2020 -54.01%
2019 -24.76%
2018 -77.87%
2017 235.71%
2016 -95.77%
2015 -94.85%
2014 -99.02%
2013 49,751,484,054.67%
2012 -60.30%
2011 3,461.02%
2010 0.00%
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Τιμή μετοχής Μεταβολή 1Έτ% Χώρα
$527.87 33.33%
US
$873.57 35.10%
NL
$745.48 9.02%
CH
$1.08K -6.68%
KR
$260.24 16.81%
BE